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1 
Introduction 
 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human 
malignancies [1], ranking 4th among causes of cancer-related death in the Western 
world [2]. Unlike most of the more frequent causes of cancer mortality (lung, colon, 
prostate and breast cancers) whose death rates are declining, the death rate for 
pancreatic cancer is increasing (figure 1).  
 
Figure 1: Trends in death rates overall and for selected sites by sex. United States, 1930 to 2011. 
Rates are age adjusted to the 2000 US standard population. Due to changes in International 
Classification of Diseases (ICD) coding, numerator information has changed over time. Rates for 
cancers of the lung and bronchus, colorectum, liver, uterus, and ovary are affected by these 
changes.  
*Mortality rates for pancreatic and liver cancers are increasing.  
†Uterus includes uterine cervix and uterine corpus [2]. 
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Exocrine pancreatic cancer is rarely curable and has an overall survival (OS) rate of 
less than 6% [1]. The highest cure rate occurs if the tumor is truly localized to the 
pancreas; however, this stage of disease accounts for less than 20% of cases. For 
patients with localized disease and small cancers (<2 cm) with no lymph node 
metastases and no extension beyond the capsule of the pancreas, complete surgical 
resection is associated with a 5-year survival rate of 18% to 24% [3]. The poor 
prognosis is reflected by a median survival of 5-8 mo and a 5-year survival of less 
than 5% when all stages are combined [4-6]. PDAC is characterized by a rapid disease 
progression and absence of specific symptoms, largely precluding an early diagnosis 
and curative treatment [6,7]. In most cases, PDAC is already locally advanced at time 
of diagnosis and only approximately 10%-20% [4,8] of patients are considered 
candidates for curative resection. The majority of patients (50%-60%) present with 
metastatic disease, and thus palliative chemotherapy remains the only option for 
almost all of these patients [9]. Owing to the high recurrence rate, surgical PDAC 
patients require adjuvant chemotherapy with or without radiotherapy providing a 5-
year survival rate of 15%-25% [10]. There is no consensus on what constitutes 
'standard' adjuvant therapy. This controversy derives from several studies, each 
fraught with its own limitations. Standards of care also vary depending on which side 
of the Atlantic you are on: chemo-radiotherapy followed by chemotherapy is 
considered the optimal therapy in North America (Gastrointestinal Tumor Study 
Group: GITSG; Radiation Therapy Oncology Group: RTOG) while chemotherapy alone 
is the current standard in Europe (European Study Group for Pancreatic Cancer: 
ESPAC-1; Charité Onkologie: CONKO) [11]. Hyperbaric oxygen therapy (HBO) is a 
complementary therapy that consists in intermittent delivery of 100% oxygen, at 
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elevated atmospheric pressures 2,5 ATA, for a short period of time (90 minutes). The 
therapy’s main effect is to elevate the oxygen dissolved within plasma and 
completely saturate hemoglobin. In cells, this means a ROS (Radical Oxygen Species) 
and RNS’ (Reactive Nitrogen Species) raised level [12], balancing by the 
contemporary increment of antioxidant enzymes [13], and increasing thickness and 
blebbing formation in cell membrane [14]. HBO is commonly used in the treatment 
of decompression sickness, carbon monoxide intoxication, arterial gas embolism, 
necrotizing soft tissue infections, chronic skin ulcers, severe multiple trauma with 
ischemia and ischemic diabetic foot ulcers [15-26]. Hypoxia is a common feature of 
solid tumors. They usually grow so rapidly to exceed their blood supply, leaving 
portions of the tumor with regions where oxygen availability is considerably limited. 
Tumor hypoxia is also due to a high degree of cell proliferation which causes higher 
cell density and thus depletes local oxygen. Hypoxic tumor cells are usually resistant 
to radiotherapy and chemotherapy because oxygen is essential for the cytotoxic 
activity of these therapies. Nevertheless, hypoxic tumors can be made more 
susceptible to treatment by increasing the amount of oxygen inside [27]. Hyperbaric 
oxygen therapy (HBO) is one of the modalities to temporarily alleviate or eliminate 
hypoxic status in growing tumor cells. By providing 100% oxygen at elevated 
atmospheric pressure, HBO increases the partial pressure of the oxygen gas and thus 
forces more oxygen to be dissolved in the plasma, which allows the extra oxygen to 
be diffused or transported to the body tissues. In vitro studies have demonstrated 
the beneficial effects of HBO used adjuvant to chemotherapy in the treatment of 
osteosarcoma, nasopharyngeal carcinoma CNE-2Z cells, and murine model of PC-3 
prostate cancer cell line and glioma U251 cell lines [28-31]. The use of HBO as 
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adjuvant therapy for pancreatic tumors has not been reported. Gemcitabine is a 
pyrimidine anti-metabolite that with good clinical activity in pancreatic, breast, 
ovarian, non-small-cell lung, and bladder tumors [32]. Gemcitabine is a first-line 
therapy for locally advanced pancreatic cancer; however, severe resistance is 
responsible for a response rate less than 20% and median survival less than six 
months [5]. Although efforts to overcome gemcitabine resistance have been made, 
the only combination treatment that has shown a small but statistically significant 
effect was gemcitabine with erlotinib, an epidermal growth factor receptor inhibitor 
[33]. We hypothesized that a combination of HBO and gemcitabine may significantly 
enhance the efficacy of gemcitabine for pancreatic tumors. In the study PANC-1 and 
AsPc-1 cells were used to investigate for the efficacy of gemcitabine-alone, HBO-
alone and the combination of both on the apoptotic index (AI) in these two cell lines. 
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Materials and methods  
 
Cell cultures. PANC-1 cell line and AsPc-1 cell line were used in the present study.  
PANC-1 is a cellular line very sensitive to gemticabine with a IC50, that represents the 
concentration of an inhibitor that is required for 50% inhibition of its target, of 
3.25x10-8 ng/mL [34]. It derived from a 56-years old man with an unserectable head 
pancreatic cancer (stage III sec. AJCC) and it was studied for the first time by Lieber 
et al in 1975 [35]. Cells presented a duplication time of 56 h [36]. 
AsPc-1 is a cellular line with moderate sensibility to gemcitabine with a IC50 of 
1.27x10-7 ng/mL [34] derived from a 62-years old man affected by an unresectable 
head pancreatic cancer stage IV sec. AJCC. This linear cell was studied for the first 
time in 1982 by Chen et al [37]. Cells presented a duplication time of 56 h [36].  
Tumor cells were derived from pancreatectomy samples from patients with 
pancreatic adenocarcinoma. Cells  from these two lines were cultured in Dulbecco’s 
modified Eagle’s medium (Sigma-Aldrich, Laborchemikalien, Seelze, Germany) with 
10% fetal calf serum and a mixture of 100 IU/ml penicillin and 100 μg/ml 
streptomycin (all from GIBCO, Grand Island, NY, USA). 
Hyperbaric chamber. A hyperbaric chamber, model Costruzioni Riunite Moro; Quinto 
di Treviso, Italy, located in Padova’s ATIP center was used for HBO therapy. The 
tumor cells were treated at 2.5 atmosphere absolute (ATA) and 100% oxygen for 90 
min, with five minutes for compression and five minutes for decompression. 
Chemotherapy. Gemcitabine (Sigma-Aldrich Laborchemikalien) was  dissolved in 
Phosphate buffered saline (PBS) and used its 50% growth-inhibitory concentration 
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(IC50) for cultured tumor cells. Its IC50 value for PANC-1 cell is 3.25×10
–8 ng/ml and for 
AsPc-1 cell is 1.27×10–7 ng/ml [34].  
Sample analysis. Apoptosis was measured quantitatively with the use of the TUNEL 
assay. The ApopTag In situ Apoptosis Detection kit (Chemicon, Temecula, CA, USA) 
was used according to the manufacturer’s instructions. A cell was considered TUNEL-
positive if it was stained brown (from light to dark) and if it exhibited  apoptotic 
bodies, chromatin condensation and membrane blebbing. The total number of 
TUNEL-positive tumor cells were counted in five different high-power fields with a 
microscope (Nikon Eclipse 80i, magnification ×20, Nikon Instruments Inc, Melville, 
NY, USA) and the average was calculated. The total number of cells (both TUNEL-
negative and -positive) was also counted and the apoptosis index was calculated. 
Treatment. Tumor cells from the PANC-1 cell line and the AsPc-1 cell  lines were 
prepared by seeding them in 35 mm Petri dishes at a density of 4000 cells/cm2 72 h 
before the beginning of the treatment. The tumor cells were divided into the 
following treatment groups. 
GEM. The tumor cells were treated with gemcitabine alone at the IC50 value. After 24 
h, the culture media were replaced. The culture media were replaced again after 24 
h and after a further 48 hours, the apoptotic index was analyzed with a TUNEL test. 
HBO. The tumor cells were treated with a quantity of PBS (as placebo) equal to that 
used for dissolving gemcitabine for administering to the experimental samples. After 
24 h, the culture media were replaced and the tumor cells were treated with HBO 
alone for 90 min at 2.5 ATA. The culture media were replaced again after 24 h and 
after a further 48 h, the apoptotic index was analyzed with a TUNEL test. 
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Control. The tumor cells were treated with PBS (as placebo) equal in quantity to that 
used to dissolve gemcitabine for administering to the experimental samples. After 24 
h, the culture media were replaced. The culture media were replaced again after 24 
h and after another 48 h the AI was analyzed with a TUNEL test. 
The composition of PBS solution (Phosphate Buffered Saline) is reported below: 
 
NaCl (SIGMA 
S7653) 
0.138 M 
KCl (SIGMA 
P9333) 
0.0027 M 
Na2HPO4 (SIGMA 
S0876) 
0.015M 
KH2PO4 (SIGMA 
P9791) 
0.0015 M 
Table 1: Composition of PBS solution. 
 
 
GEM-HBO. Gemcitabine, at the IC50 value for the tumor cells was administered the 
tumor cells cultured for 24 h. The drug was then eliminated by replacing the culture 
media. The tumor cells were then treated with HBO at 2.5 ATA for 90 min. The 
culture media were replaced 24 h later. The apoptotic index was analyzed with a 
TUNEL test after 48 h.  
HBO-GEM. The tumor cells were first treated with HBO at 2.5 ATA  for 90 min. After 
24 h, the culture media were replaced and the tumor cells were treated with 
gemcitabine at the IC50 value. After 24 h, the culture media were replaced again and 
after another 48 h, the AI was analyzed with a TUNEL test. 
HBO+GEM. Gemcitabine at the IC50 value for the tumor cells was administered and 
HBO was administered for 90 min at 2.5 ATA at the same time. After 24 h, the 
culture media were replaced and after a further 48 h, the apoptotic index was 
analyzed with a TUNEL test. 
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Each treatment was repeated three times and for each sample, the cells in 23 
randomly selected fields of 0.157 mm2 within a 5 cm2 area were counted for 
apoptotic and living cells. During the measuring of apoptotic cells, the number of all 
tumor cells in each group was counted to determine the tumor cell growth under 
different treatments. 
Apoptotic Index (AI). The AI was calculated as: AI=total number of apoptotic cells 
counted/ total number of live cells counted. 
Statistical analysis. Results are presented as the mean±SD. Multiple comparisons 
among groups were analyzed by one-way analysis of variance followed by the 
Tukey–Kramer method for post-hoc analysis after confirmation of normal 
distribution of the data. Tukey 95% simultaneous confidence intervals were applied, 
or p-value <0.05, when equality assumptions were rejected simultaneously. The 
individual confidence level was 99.54%, or with p-value <0.0046. 
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Results 
 
The apoptotic indices are summarized in Table 2. HBO per se had no significant effect 
on the induction of apoptosis in either cell line. HBO when administrated before or 
after gemcitabine administration also had no significant effect on gemcitabine-
induced apoptosis in either cell line. HBO enhanced gemcitabine-induced apoptosis 
in both tumor cell lines only when administrated concurrently with gemcitabine. 
There was no significant change in the total number of tumor cells with therapy 
using HBO-alone or the control group (data not shown).   
 
 
Treatment 
Cell lines Control HBO GEM HBO-GEM GEM-HBO HBO+GEM 
PANC-1 5.9±0.1 6.5±0.1 8.1±0.1*# 8.2±0.1*# 8.5±0.1*# 10.7±0.1*#! 
AsPc-1 5.9±0.1 5.9±0.1 8.0±0.1*# 8.2±0.1*# 8.4±0.1*# 9.7±0.1*#! 
Table 2: Effect of hyperbaric oxygen (HBO) treatment and gemcitabine (GEM) on apoptosis of PANC-
1 and AsPc-1 pancreatic ductal adenocarcinoma cells. Apoptotic indices are presented mean±SD. 
HBO per se had no significant effect on apoptosis of tumor cells. Gemcitabine significantly induced 
apoptosis of tumor cells. HBO significantly enhanced gemcitabine-induced apoptosis only when 
administrated during chemotherapy. The number of tumor cells for each group was 4x10
3
 cells/cm
2
 
in Petri dish.  Control: without treatment; HBO: treated with HBO alone for 90 min at 2.5 ATA; GEM: 
treated with GEM alone; HBO-GEM: treated with HBO at 2.5 ATA for 90 min then after 24 h treated 
with GEM; GEM-HBO: treated with GEM for 24 h then placed in drug-free culture media and treated 
with HBO; HBO+GEM: HBO was administrated for 90 min at 2.5 ATA during therapy with GEM.  
*p<0.01 vs control; 
#
 p<0.01 vs HBO; 
!
 p<0.01 vs GEM, HBO-GEM and GEM-HBO. 
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Discussion 
 
Despite the improved survival rates noted in numerous cancers, including breast [38-
40], prostate [41] and colon cancer [42], the overall survival rates for patients 
diagnosed with pancreatic cancer have shown little improvement over the past thirty 
years [43-45]. PDAC remains one of the most rapidly progressive and deadly 
malignancies worldwide [2]. The prevention of pancreatic cancer is difficult to assess, 
due to limited studies identifying potential risk factors compounded with the 
multifactorial, heterogeneous nature of the disease. Cigarette smoking has been 
noted to double the risk of pancreatic cancer, yet only accounts for 20%-25% of the 
cases [46,47]. Additionally, family history may also contribute a significant role as 
5%-10% of individuals with pancreatic cancer report an incidence of pancreatic 
cancer in a close family member [48]. This risk is further substantiated when there is 
a larger number of family members with pancreatic cancer and a decrease in age of 
onset in kindred [49]. Other noted risk factors include alcohol abuse [50], a high-fat 
diet [51,52], and certain trace elements [53]. The challenge of diagnosing PDAC at an 
early stage further contributes to the dismal five-year survival rate that is projected 
for patients. Located in the retroperitoneum of patients who present with non-
specific symptoms, PDAC is not diagnosed until it has reached an advanced clinical 
stage in 80% of patients [54]. In addition, lack of effective screening and early 
biomarker detection methods have prevented clinicians from identifying this cancer 
in a pre-malignant stage. Ideally, visual evaluation via computerized tomography (CT) 
and magnetic resonance imaging (MRI) should be incorporated upon suspicion of 
pancreatic cancer for detection and respectability assessment [55]. Although CT scan 
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has often been utilized to detect pancreatic cancer [56,58], reliance on MRI, 
particularly in regard to assessing local invasion and metastasis, has increased [59]. 
Other imaging may also provide certain benefits, such as endoscopic ultrasound for 
investigating vascular invasion [60], fludeoxyglucose-positron emission tomography 
scanning for recurrent tumors [61], and laparoscopy for more accurate staging [62]. 
While the use of these techniques remains helpful to determine prognosis and 
treatment regimen for patients diagnosed with pancreatic cancer, none have been 
validated as effective screening tests for general or high risk populations. Once 
diagnosed, a number of chemotherapy, radiation and combination therapy regimens 
have been used to treat patients with ductal pancreatic tumors. Unfortunately, the 
dynamic molecular and cellular makeup of individual pancreatic tumors, renders 
many of them resistant to the majority of these therapies. Although surgical 
resection has been shown to increase patient survival by 10 mo [63], the majority of 
patients who undergo these procedures experience comorbidities and recurrence. 
Current research has identified additional sources of therapeutic resistance in the 
microenvironment of these tumors. Characterized by stromal proliferation, reduced 
angiogenesis and a unique subset of cells known as cancer stem cells (CSCs), the 
tumor microenvironment has become a target of new therapeutic agents. 
While improved understanding of pancreatic cancer biology has lead to several 
therapeutic breakthroughs in the treatment of PDAC, major progress toward 
improving survival rates in patients has been extremely slow. However, as our 
understanding of this tumor’s therapeutic resistant nature improves, so will future 
progress in treating pancreatic cancer. There is no consensus on what constitutes 
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'standard' adjuvant therapy. This controversy derives from several studies, each 
fraught with its own limitations [64].  
The GITSG trial was the first prospective randomized trial suggesting survival 
advantage with postoperative chemo-radiotherapy using bolus 5-FU (median 
survival: 20 months vs. 11 months and 5-year survival:18% vs. 8%) [65]. However this 
study was criticized for poor patient accrual, early termination, and small patient 
numbers, and some maintained that the radiotherapy dose was suboptimal (some 
authors advocate 50 Gy as a total effective dose). Multiple authors have attempted 
to confirm its findings. The European Organization of Research and Treatment of 
Cancer (EORTC) compared 5-FU (25 mg/kg/day continuous infusion for 5 days every 
4 weeks) with concurrent radiotherapy using a split course (40 Gy) with observation 
only in patients with resected pancreatic and periampullary cancer [66]. Klinkenbijl 
et al were able to show a trend toward benefit in terms of median survival (24.5 
months vs. 19.0 months; p=0.208). The subgroup analysis looking only at pancreatic 
cancer patients showed a trend toward benefit in median survival (17.1 months vs. 
12.6 months; p=0.099) [66]. This study too was criticized for suboptimal dose of 
radiotherapy and split courses. Lower radiotherapy dose and split courses that may 
have allowed cancer repopulation between courses thereby under-estimating the 
benefit of chemo-radiotherapy. Although not conclusive, these results showed a 
trend toward benefit of adjuvant therapy and led to the ESPAC-1 trial, the largest 
reported randomized study to date investigating the role of combination chemo-
radiotherapy in pancreatic cancer [67]. This study, in fact, has sparked a new debate 
over the role of radiotherapy in the adjuvant therapy of pancreatic cancer. ESPAC-1 
trial was 2x2 factorial designed study comparing adjuvant concurrent chemo-
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radiotherapy (bolus 5-FU/split course radiotherapy), chemotherapy alone (5-
FU/leucovorin), chemo-radiotherapy followed by chemotherapy, and observation. 
Chemotherapy only arm had statistically significant benefit over observation arm in 
median survival (20.1 months vs. 15.5months; p=0.009). However, 
chemoradiotherapy arm showed worse median survival compared with patients who 
did not receive chemo-radiotherapy (15.9 months vs.17.9 months; p=0.05) [66]. 
Interpretation of this study is complicated slightly because two different study 
designs are used: a 2x2 factorial design and direct head-to-head comparisons 
(chemotherapy vs. no chemotherapy and chemo-radiotherapy vs. no chemo- 
radiotherapy). Eligible patients were pre-enrolled in one of the above strategies. The 
authors then reported their findings for each of the separate study designs as well as 
for the pooled data. Therefore, major criticism  was made on this study for possible 
selection bias as both patients and clinicians were allowed to select which trial to 
enter, a concern of suboptimal radiotherapy, and for allowing the final radiotherapy 
dose to be left to the judgment of the treating physicians. Moreover, the treatment 
for patients in the chemo-radiotherapy group did not include post-radiotherapy 
adjuvant chemotherapy, making direct comparison to the GITSG trial difficult. The 
ESPAC-1 study uses only a 5-FU-based chemotherapy regimen; and certainly, a 
gemcitabine-based approach is the most logical place to start, which was  evaluated 
in the RTOG 9704 study. RTOG 9704 study randomized 538 resected pancreatic 
cancer patients to evaluate benefit of adding gemcitabine to infusional 5-FU 
combined with radiotherapy [68]. One arm received 5-FU plus radiotherapy and the 
other arm was treated with gemcitabine before and after 5-FU plus radiotherapy. 
Patients with pancreatic head tumors (No. 380) showed benefit in median survival 
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(18.8 months vs.16.7 months; p=0.047) by the incorporation of gemcitabine before 
and after 5-FU plus radiotherapy. However, there was no significant difference when 
pancreatic body and tail cancers were all included. While benefit of radiation therapy 
was inconclusive in randomized trials, Oettle et al published the results of CONKO-
001 study in JAMA in 2007 [69]. CONKO-001 study randomized 368 patients with 
resected pancreatic cancer to gemcitabine or observation for 6 months. Tumor 
prognostic characteristics were similar in both arms. This trial showed statistically 
significant disease free survival benefit (13.4 months vs. 6.9 months; p<0.001) of 
gemcitabine over observation. Gemcitabine rendered a trend toward overall benefit 
(22.1 months vs. 20.2 months; p=0.06). This benefit of chemotherapy was consistent 
with the result from ESPAC-1 trial which showed benefit of 5-FU/leucovorin over no 
adjuvant therapy in pancreatic cancer patients (median survival of 19.7 months vs. 
14.0 months) who had complete resection [67]. The CONKO-001 study has many 
worth mentioning points. Gemcitabine, the current standard of care in first line 
treatment, has clearly showed superiority over 5-FU in patients with advanced 
pancreatic cancer, both in terms of dramatic improvement in clinical benefit 
response as well as a modest improvement in median survival [70]. Therefore, 
ESPAC-1 (in which 5-FU was the chemotherapy agent of choice) and the Burris et al 
study both provide a rationale for choosing gemcitabine arm in CONKO-001 study 
[67,70]. CONKO-001 study also reconfirmed that single-agent chemotherapy with 
gemcitabine was generally well-tolerated in this study and most of the patients were 
able to complete the full six cycles of treatment [69]. On the other hand, the median 
disease free survival of patients in the observation-only was dismal (less than 7 
months), underlying the fact in addition to further improve the adjuvant treatment 
15 
regimens, specialized surgeries such as Whipple’s procedure should preferentially be 
carried out at high volume centers by experienced surgeons, where outcomes are 
known to be better [71]. Recent studies demonstrated that neoadjuvant 
chemoradiation is safe with respect to toxicity, perioperative morbidity, and 
mortality [72,73].  
The cellular mechanisms of therapeutic resistance in pancreatic cancer are not clear, 
but the mutations for the KRAS2 oncogene, resulting in the constitutive production 
of the Ras protein [74-77] maybe is important. Occurring early in tumorogenesis, 
these point mutations are essential for maintaining the malignant phenotype 
because once activated, Ras initiates a signal transduction cascade that activates 
proliferative and cell survival pathways and increases cell invasion [78,79]. The 
majority of the point mutations occur on codon 12 of the ras protein and give rise to 
pancreatic tumor-specific neo-antigens. The mutations of K-ras stimulate the 
extracellular proliferation of leukocytes, fibroblasts, endothelial cells, neuronal cells, 
collagen and hyaluron. This extracellular proliferation of cells is known as a 
desmoplastic reaction. The desmoplastic reaction not only provides a mechanical 
barrier to the pancreatic cancer cells, but it is also thought to contribute to the anti-
angiogenic environment that is characteristic of PDAC. 
Rather than being activated like the mutated KRAS2 oncogene, the p53 tumor 
suppressor gene is inactivated in 75%-90% of pancreatic tumors. As a result, there is 
an impaired response to DNA damage in pancreatic epithelial cells, impaired 
apoptosis and impaired cell cycle control. Two other tumor suppressor genes, 
p16Ink4a and p15ARF are encoded by the cdkn2a locus. Inactivation mutations in 
these genes are present in about 90% of human PDAC. A fourth common mutation 
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seen in more than half of pancreatic cancers causes an alteration in DPC4 (Deleted 
Pancreatic Cancer, locus 4 cromosome 18). DPC4 is a gene that codes for a protein 
important in the TGF-β superfamily of signaling pathways. The knock out of the TGF-
β gene in a cancer cell, also inactivated the TGF-β pathway. These pathways usually 
act to promote differentiation (maturation to normal adult forms) and to slow the 
growth of cells. TGF-β has a role in humans similar to that in other species, and most 
normal cells stop proliferating when exposed to TGF-β. So, the mutations of DPC4 
confer a metastatic phenotype [64].  
In this study we analyzed the role of a single treatment with hyperbaric oxygen in 
pancreatic ductal adenocarcinomas cells, wondering if oxygen plays a role as 
promoter the tumor cells growing, as inhibitor the tumor cell growing or as adjuvant 
a chemotherapeutic drug’s activity, in our case, gemcitabine. The main findings of 
the present study are that:  
i: HBO alone had no significant effect on inducing tumor cell apoptosis;  
ii: gemcitabine-alone significantly increased apoptosis of tumor cells;  
iii: administration of HBO before or after gemcitabine treatment did not further 
increase apoptosis;   
iv: administration of HBO concurrently with gemcitabine treatment significantly 
enhanced gemcitabine induced apoptosis of the tumor cells.   
A possible mechanism of HBO mediating beneficial effects has been described as 
attenuation of the production of proinflammatory cytokines in response to an 
inflammatory stimulus such as surgery [80-82] and modulation of the immune 
response [82-84]. In fact, HBO is known to promote new vessel growth into areas 
with reduced oxygen tension due to poor vascularity, and therewith promotes 
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wound healing and recovery of radiation-injured tissue. Hyperbaric oxygen therapy 
applies, according to HUMS guide lines [85], can be use to treat all pathologic 
conditions where hypoxia or ischemia are clinically relevant. In the last years, many 
studies evaluate HBO efficacy in treating tumors [86]; in fact in solid tumors there are 
extended hypoxic areas [87] so it may be rational to use hyperbaric oxygen therapy. 
There are evidence that HBO therapy could elevate oxygen delivery to hypoxic cells 
and so increase their susceptibility to radiotherapy or chemotherapy [86,88]. The 
correlation between hypoxia and tumor growth is unclear, but there is a correlation 
between hypoxia and Hypoxia Inducible Factor (HIF)-1α. HIF-1α is a transcription 
factor that regulates the transcription of genes associated with cell proliferation and 
vascular development. In various cancer tissues, HIF-1α is associated with 
clinicopathological factors, such as the tumor size, histological grade, and lymph 
node status. Although HIF-1α plays a critical role in tumor growth by inducing 
vascular endothelial growth factor (VEGF), it is unclarified whether HIF-1α affects 
lymphatic metastasis. As dimostrated by Katsuta et al [89]  in esophageal squamous 
cell carcinoma (ESCC),  the expressions of HIF-1α and VEGF-C, which is one of the 
main lymphangiogenic factors, were expressed in all ESCC cell lines. 
Immunohistochemically, 34 of the 48 patients (70.8%) were positive for HIF-1α and 
29 patients (60.4%) were positive for VEGF-C. Clinicopathologically, HIF-1α 
expression correlated with lymphatic invasion and VEGF-C expression (p=0.003 and 
p=0.01, respectively). Furthermore, HIF-1α expression tended to correlate with 
lymph node metastasis (p= 0.09). These findings suggest that HIF-1α plays a role in 
lymphatic invasion and lymph node metastasis through the induction of VEGF-C in 
ESCC. In a very recent paper, Wang et al demonstrated that Reactive Oxygen Species 
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(ROS) can drive the de-differentiation of tumor cells leading to the process of 
epithelial-to-mesenchymal transition (EMT) to enhance invasion and metastasis by 
the HIF-1α/LOX/E-cadherin via. The invasive and metastatic phenotype of malignant 
cells is often linked to loss of E-cadherin expression, a hallmark of EMT. The hypoxic 
exposure causes HIF-1α -dependent repression of E-cadherin. Wang et al found that 
ROS accumulation in ovarian carcinoma cells upregulated HIF-1α expression and 
subsequent transcriptional induction of lysyl oxidase (LOX) which repressed E-
cadherin. Loss of E-cadherin facilitated ovarian cancer (OC) cell migration in vitro and 
promoted tumor growth in vivo [90].  
In a very interesting paper, Zhu et al in 2013 [91] demonstrated that HIF-1α plays a 
crucial role in the maturation process from Cancer staminal cells (CSCs) naïve in CSCs 
CD133+. CD133 is a marker protein typically used to identify and isolate human 
pancreatic CSCs [92]  
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Figure 2: Expression of HIF-1 in human cancer: causes and consequences [87]. 
 
In fact, under hypoxic conditions, HIF-1α subunits translocate to the nucleus, where 
they heterodimerize with HIF-1β subunits. The resultant product is an active HIF-1 
protein that binds to specific hypoxic response elements present in target genes, 
ultimately activating transcription of these genes. In particular, Vaupel [87] 
demonstrated that under hypoxic conditions, HIF-1β dimerizes with HIF-1α and the 
active HIF-1 dimer binds to hypoxia response elements containing the core 
recognition sequence 5’-RCGTC-3’ and then recruits coactivator molecules, resulting 
in the formation of an increased transcription initiation complex and mRNA 
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synthesis, leading ultimately to the biosynthesis of proteins that mediate responses 
to hypoxia.   
 
Figure 3: Regulation of HIF-1α by cellular O2 level [87]. 
 
Solid tumors survive and proliferate in a hypoxic environment. These slowly-
proliferating hypoxic tumor cells are less susceptible to chemotherapy and 
radiotherapy because molecular oxygen and reactive oxygen species (ROS) are 
essential for such therapies. Therapeutic efficacy may be improved if the hypoxic 
state of the tumor cells is eliminated. HBO is one of the modalities to significantly 
increase oxygen availability around tumor cells and thus has been evaluated as 
adjuvant to radiotherapy and chemotherapy. It has been a concern that HBO induces 
re-oxygenation of hypoxic tumor cells and an increase of angiogenesis may 
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potentially promote tumor cell growth and recurrence of malignancy [86]. 
Comprehensive investigations are mandatory before HBO can be safely used in 
clinical cancer therapy. 
Tang et al investigated the effect of HBO on tumor growth in an in vivo murine 
model of indolent prostate cancer [93]. Mice with induced tumors were randomized 
to undergo 20 sessions of either therapy with HBO or air, under standardized 
conditions and were observed for 4 weeks before histological assessments of any 
palpable tumors that had developed. It was found that exposure to HBO had no 
effect on prostate cancer volume, tumor microvessel density, proliferative index, and 
apoptosis markers in comparison to the non-HBO group. Their study showed that 
HBO had no tumor-stimulatory effect on prostate cancer. They suggested that HBO 
may potentially be used safely in conjunction with other therapeutic modalities [93]. 
Lu et al also reported that HBO inhibited proliferation in glioma U251 cells in vitro 
[94]. The natural doubling time for the tumor cells used in the present study was 
approximately 52 h. The proliferation of tumor cells was not examined in the present 
study because treatment caused changes that may not be detectable 24 h after 
treatment [93].  Nevertheless, we did record tumor cell numbers in the group 
treated with HBO-alone and control group and found there was no significant 
difference in the cell numbers in both groups, therefore ruling out a possible 
stimulating effect of HBO on growth. As mentioned by Schonmeyr et al, conflicting 
results on the effects of HBO on tumors have been presented [95]. Thus, some 
studies have shown suppressed tumor growth and reduced metastatic rates after 
HBO [96,97]; others have demonstrated enhanced tumor progression or no effects 
at all [98,99]. Schonmeyr et al showed that HBO does not accelerate squamous cell 
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proliferation or promote tumor growth. Furthermore, their data showed that 
although HBO may decrease hypoxia within the tumors, there is no evidence of HBO 
altering angiogenesis or vascular invasion in squamous cancer cell tumor deposits 
[95]. Our study is in agreement with the above findings that HBO has no tumor-
stimulating effect in the pancreatic tumor cell lines studied. Lu et al reported that 
HBO-alone inhibited cell proliferation and induced apoptosis of glioma U251 cells in 
vitro [94].  In our study, HBO-alone had no significant effect on the AI for pancreatic 
tumor cells. It is known that HBO increases the free oxygen radical level, which may 
cause tumor cell damage. In their study, HBO was given three times at 12 h intervals. 
Multiple HBO sessions may exceed the tumor cells’ endogenous cellular antioxidant 
capacity, thus creating oxidative stress leading to cell damage. Consistent with the 
evidence that most chemotherapy agents cause tumor cell death primarily by 
inducing apoptosis, resistance to anticancer treatment is widely believed to involve 
mutations that lead to de-regulated cellular proliferation and suppression of 
mechanisms that control apoptosis. It has been observed that tumors with exhibiting 
AI after one cycle of chemotherapy are more likely to achieve pathological 
regression. Increased apoptosis after chemotherapy may also predict which patients 
will have a good pathological response [100]. The utility of HBO as adjuvant therapy 
in tumor treatment is still under investigation. Bradfield et al observed four patients 
with head and neck cancer who apparently had rapid progression of clinically-occult 
disease during or soon after undergoing HBO [101]. However, other studies have 
reported on the beneficial effect of HBO as adjuvant therapy in tumor treatment. 
Haffty et al conducted a randomized clinical trial to evaluate the role of HBO as 
adjuvant to radiotherapy in the treatment of locally advanced squamous cell 
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carcinoma of the head and neck [102]. The patients were randomized to radiation-
alone or radiation under HBO over 21 days to at total of 23 Gy. There was a highly 
significant difference in complete clinical responses between the two groups, with 
21/25 complete clinical responses in the HBO treated group compared with 13/25 
complete clinical responses in the control group, and a statistically insignificant trend 
towards improved 5-year local control in the HBO treated group (29% vs. 16%). 
There were no significant differences between the two groups with respect to 5-year 
survival, distant metastasis, or second primary tumors. They concluded that the long-
term outcomes from their randomized trial demonstrated substantial improvements 
in response rate after use of HBO. McDonald et al conducted a study using chemical 
carcinogen-induced squamous cell carcinoma in Golden Syrian hamsters to 
determine the effects of HBO on tumor management [103]. Twenty hamsters 
underwent 30 HBO seasons for 60 min each to 2.81 ATA, while 20 untreated served 
as controls. At necropsy, animals receiving HBO had significantly smaller tumors and 
had a trend toward fewer cervical metastases. Ohgami et al also demonstrated that 
HBO enhanced anticancer activity of artemisinin in Molt-4 human leukemia cells 
resulting in an additional 22% decrease in growth [104]. The present study shows 
that HBO, only when simultaneously administered with gemcitabine significantly 
increased apoptosis of pancreatic tumor cells in vitro. Time may be an important 
factor to determine the efficacy of therapeutic management. A clinical trial showed 
that radiotherapy delivered immediately after HBO with chemotherapy was safe, 
with virtually no late toxicities, and seemed to be effective in patients with high-
grade gliomas [105]. 
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An in vitro study using highly metastatic murine osteosarcoma cell lines found that 
HBO-alone significantly suppressed cell proliferation, and HBO-plus carboplatin 
exhibited significant synergism in suppression of cell proliferation. Authors also 
reported that concomitant HBO clearly enhanced the chemotherapeutic effects of 
carboplatin on both tumor growth and lung metastasis in osteosarcoma-bearing 
mice [86]. Further study is needed to find an ideal HBO regime to maximize its 
enhancing effect for chemotherapy and minimize its adverse effect. In the present 
study, there was no effect on apoptosis if HBO was administered either before or 
after chemotherapy. 
Since our study was in vitro, the tumor cells were placed under an oxygen-rich 
environment only when HBO was provided. Enhanced antitumor activity of 
gemcitabine occurred only when tumor cells were under hyperbaric hyperoxic 
condition. Our study supports the notion that HBO may be useful as adjuvant to 
chemotherapy in the management of cancer treatment [106]. Our study also 
suggests that the time window may be critical for using HBO during chemotherapy. 
Although is still not fully-understood, multiple mechanisms may be responsible for 
the enhancement of gemcitabine induced apoptosis by HBO. HBO has been reported 
to directly increase the uptake of 5-fluorouracil in dimetyl-α- benzantracene-induced 
mammary tumors in vivo [107]. It is known that some chemotherapeutic drugs 
require oxygen to enerate free oxygen radicals that in turn induce cytotoxicity. 
HBO may disturb the membrane components of cells following oxidation 
phenomena caused by ROS overproduction. A change in the properties of any one 
membrane components is anticipated to change the conductance of membrane-
spanning ion channels and thus cell function. HBO therefore may facilitate drug 
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access to the cell, if the drug is already close to the cell. HBO may also slow down the 
elimination of the drug due to inhibition of protein response, increase membrane 
thickness, or oxidation of the amino acids of transport proteins, in particular of 
multidrug resistance proteins, thanks to increasing intracellular ROS [94,108]. 
Multidrug resistance arises primarily due to the up-regulation of proteins from the 
adenosine triphosphate binding cassette transporter family. Sensitivity to 
chemotherapy is strongly dependent on the expression of multidrug-resistance 
related transporters [109]. HBO has been observed to inhibit multi drug-resistance-
related transporters therefore enhancing anticancer activity of chemotherapy [93].  
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Conclusions 
 
Finally, TNF-α is implicated in the processes of tumor growth, survival, 
differentiation, invasion, metastasis, secretion of cytokines and pro-angiogenic 
factors. HBO has been reported to inhibit TNF-α production in ischemia reperfusion 
tissue injury [110,111]. HBO was also reported to reduce interleukin-1 production of 
macrophage [112]. Since interleukin-1, in particular, is able to stimulate metastasis 
and growth of the cell lines we used here, HBO might enhance apoptosis by 
inhibiting its production [113]. The HBO is also important in the regulation of HIF-1α 
level [91].  
In summary, HBO-alone was found to have no effects on apoptosis of pancreatic 
tumor cells in vitro. HBO did not enhance gemcitabine-induced apoptosis of 
pancreatic tumor cells when administered before or after chemotherapy. HBO 
significantly enhanced gemcitabine-induced apoptosis of pancreatic tumor cells 
when administered concomitantly with chemotherapy. Our study suggests that the 
time window of therapy is critical for effectively using HBO as adjuvant to 
chemotherapy. 
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